Jerusalem, 5 June, 2025 (TPS-IL) — Israel’s Elgan Pharma and Italy’s Chiesi Farmaceutici have begun dosing infants in a Phase 3 clinical trial of ELGN-2112, a potential breakthrough treatment for intestinal malabsorption in preterm babies. The global FIT-PIV study will enroll 420 infants across 50 sites, aiming to improve gastrointestinal function and reduce complications linked to intravenous feeding.
ELGN-2112, an enteral insulin formulation, has shown promise in accelerating nutritional development in earlier trials. The Israeli-Italian collaboration marks a significant step toward addressing a serious and often life-threatening condition affecting premature infants worldwide.